"Pre-Clinical Advancements to Reduce Attrition Rates in Biologic Drug Discovery" a Webinar Hosted by Selexis SA

News provided by

Selexis SA

Feb 27, 2014, 07:30 ET

Geneva, Switzerland (PRWEB) February 27, 2014 -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the SURE CHO-Mplus™ Libraries to address a broad range of protein production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications to boost the overall expression of therapeutic protein drugs.

Entitled “Pre-Clinical Advancements to Reduce Attrition Rates in Biologic Drug Discovery,” the 60 minute webinar will begin at 10:00 AM PT | 1:00 PM ET | 7:00 PM CET on Tuesday, March 25, 2014.
Registration URL: https://attendee.gotowebinar.com/register/577515540591333121
Webinar ID: 118-477-131

In this webinar you will learn:

  • An overview of the SURE CHO-M production cell line
  • The construction of the SURE CHO-Mplus™ combinatorial library
  • How to implement the SURE CHO-Mplus™ Libraries platform to efficiently advance drug discovery and protein production programs
  • Case studies utilizing the SURE CHO-Mplus™ Libraries

Who should attend?

  • Any scientist working with recombinant protein either as a target or as a future drug
  • Cell line development scientists and researchers
  • Biologics development scientists
  • Cellular biochemists

When:
Tuesday, March 24, 2014
10:00 AM PT | 1:00 PM ET | 7:00 PM CET
50 minute presentation
10 minute Q/A

Where:
Registration URL: https://attendee.gotowebinar.com/register/577515540591333121
Webinar ID: 118-477-131

Webinar Abstract:
Pre-Clinical Advancements to Reduce Attrition Rates in Biologic Drug Discovery
A number of factors, such as expression levels and proper folding, significantly influence the success rate of biologics during the development stage. With certain recombinant proteins, the optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within Selexis' SURE CHO-MplusT Libraries, a variety of cellular pathway components have been modified to address specific bottlenecks, such as aberrant glycosylation, improper protein folding, metabolic or translation issues. The SURE CHO-MplusT Libraries has been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.

About the Speaker:
Pierre-Alain Girod, PhD, Chief Scientific Officer
Dr. Girod joined Selexis in 2006 and was promoted to Chief Scientific Officer in 2007. Dr. Girod studied and received his PhD from the University of Lausanne. Prior to joining Selexis, Dr. Girod worked at the Department of Biology at the University of Lausanne in the field of targeted protein degradation. Earlier in his career, Dr. Girod completed a postdoctoral fellowship at the University of Wisconsin-Madison in the degradation of proteins by the ubiquitin pathway. In 1993 he returned to Switzerland where he discovered a family of genetic sequences involved in the epigenetic regulation of genes. This discovery has subsequently been used to by pharmaceutical and biotechnology companies to boost expression of therapeutic proteins.

To learn about about the Selexis SURE CHO-Mplus™ Libraries
Visit http://www.youtube.com/watch?v=g9kHXeDZOH4

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:

Robert Meister, Selexis SA, http://www.selexis.com, 602-953-1716, [email protected]